Keywords:
дилатационная кардиомиопатия, внутривенный иммуноглобулин, иммуномодуляция, аутоиммунное воспаление, цитокины.References
Elliott P., Andersson B., Arbustini E., Bilinska Z., Cecchi F., Charron P., Dubourg O., Kühl U., Maisch B., McKenna W.J., Monserrat L. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008; 29 (2): 270-276. DOI: https://doi.org/10.1093 /eurheartj/ehm342
Arbelo E., Protonotarios A., Gimeno J.R., Arbustini E., Barriales-Villa R., Basso C., Bezzina C.R., Biagini E., Blom N.A., De Boer R.A., De Winter T. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44 (37): 3503-3626. DOI: https://doi.org/10.1093/eurheartj/ehad 194
Zhang J., Cheng L., Li Z., Li H., Liu Y., Zhan H., Xu H., Huang Y., Feng F., Li Y. Immune cells and related cytokines in dilated cardiomyopathy. Biomed Pharmacother. 2024; 171: 116-159. DOI: https:// doi.org/10.1016/j.biopha.2024.116159
Wang J., Duan Y., Sluijter J.P., Xiao J. Lymphocytic subsets play distinct roles in heart diseases. Theranostics. 2019; 9 (14): 4030–4046. DOI: https: //doi.org/10.7150/thno.33112
Ohlow M.A., Brunelli M., Schreiber M., Lauer B. Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry. J Cardiol. 2017; 69 (2): 409-416. DOI: https://doi.org/ 10.1016/j.jjcc.2016.07.014
Sorella A., Galanti K., Iezzi L., Gallina S., Mohammed S.F., Sekhri N., Akhtar M.M., Prasad S.K., Chahal C.A.A., Ricci F., Khanji M.Y. Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations. Eur Heart J Qual Care Clin Outcomes. 2025; 11 (2): 206-222. DOI: https://doi.org/10.1093 /ehjqcco/qcae109
Felix S.B., Staudt A., Dörffel W.V., Stangl V., Merkel K., Pohl M., Döcke W.D., Morgera S., Neumayer H.H., Wernecke K.D., Wallukat G. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000; 35 (6): 1590-1598. DOI: https://doi.org/10.1016/s0735-1097(00)0056 8-4
McNamara D.M., Holubkov R., Starling R.C., Dec G.W., Loh E., Torre-Amione G., Gass A., Janosko K., Tokarczyk T., Kessler P., Mann D.L. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001; 103 (18): 2254-2259. DOI: https://doi.org/10.1161/01.cir.10 3.18.2254
Robinson J.L., Hartling L., Crumley E., Vandermeer B., Klassen T.P. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord. 2005; 5 (1): 12. DOI: https://doi.org/10.1186/1471-2261-5-12
Aukrust P., Yndestad A., Damås J.K., Gullestad L. Inflammation and chronic heart failure–potential therapeutic role of intravenous immunoglobulin. Autoimmun Rev. 2004; 3 (3): 221-227. DOI: https:// doi.org/10.1080/07853890510007232
Goland S., Czer L.S., Siegel R.J., Tabak S., Jordan S., Luthringer D., Mirocha J., Coleman B., Kass R.M., Trento A. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature. Can J Cardiol. 2008; 24 (7): 571-574. DOI: https:// doi.org/10.1007/s00246-024-03450-8
Yen C.Y., Hung M.C., Wong Y.C., Chang C.Y., Lai C.C., Wu K.G. Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: a systematic review and meta-analysis. Sci Rep. 2019; 9 (1): 10459. DOI: https://doi.org/10.1038/s41598-019-46888-0
Hazebroek M.R., Henkens M.T., Raafs A.G., Verdonschot J.A., Merken J.J., Dennert R.M., Eurlings C., Abdul Hamid M.A., Wolffs P.F., Winkens B., Brunner‐La Rocca H.P. Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controlled clinical trial. Eur J Heart Fail. 2021; 23 (2): 302-309. DOI: https://doi.org/10.1002/ejhf.2082
Mobini R., Maschke H., Waagstein F. New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. Autoimmun Rev. 2004; 3 (4): 277-284. DOI: https://doi.org/10.1016/j.autrev.200 3.10.005